Clinical Cancer Research Versailles No Abst Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Granelli, P.
Right arrow Articles by Biunno, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Granelli, P.
Right arrow Articles by Biunno, I.
Clinical Cancer Research Vol. 10, 5857-5861, September 1, 2004
© 2004 American Association for Cancer Research


Molecular Oncology, Markers, Clinical Correlates

SEL1L and Squamous Cell Carcinoma of the Esophagus

Paola Granelli1, Monica Cattaneo2, Stefano Ferrero3, Luca Bottiglieri3, Silvano Bosari3, Giuseppe Fichera1 and Ida Biunno2,4

1 Dipartimento di Scienze Chirurgiche e Trapianti, Ospedale Maggiore Policlinico Milano Istituto di Ricovero e Cura a Carattere Scientifico, Milan; 2 Istituto Tecnologie Biomediche, Consiglio Nazionale delle Ricerche, Segrate-Milan; 3 Dipartimento di Medicina Chirurgica e Odontoiatria, Ospedale S. Paolo e Istituto di Ricovero e Cura a Carattere Scientifico Ospedale Maggiore, Università degli Studi di Milano, Milan; 4 Centro Interdisciplinare Studi Bio-molecolari e Applicazioni Industriali (CISI) Università di Milano, Milan, Italy

The gene SEL1L is involved both in human breast and pancreatic cancer progression. It is located on 14q24.3–31, a region known to be lost in invasive cancer of the esophagus. We aimed to assess whether SEL1L could become a useful biomarker for this cancer. We assessed SEL1L mRNA and protein expression in 35 patients and found it to be weak in low-grade and strong in high-grade dysplasia. Although the majority of cancer patients showed differential expression (mRNA and protein) of SEL1L, in five cases it was completely absent; these patients had the worst outcomes. SEL1L immunoreactivity was negative in normal tissue samples from five patients with mild esophagitis as well as in normal mucosa adjacent to the tumor. We hypothesize that SEL1L could influence those cellular changes that mediate the transition from a normal mucosa to a neoplastic lesion and may help in the identification of those patients at higher risk of developing this cancer. The specific impact of SEL1L in esophageal cancer needs further investigation.







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2004 by the American Association for Cancer Research.